As per a media report over the weekend, AstraZeneca Plc (NYSE:AZN) and Bristol Myers Squibb Co. (NYSE:BMY) are in potential discussions to form a pharmaceutical giant valued at nearly $400 billion.The news took the healthcare sector by storm, and the merger would position AstraZeneca as the world’s…
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.
After the biotech sector's worst month in more than a year, a potential combination between AstraZeneca (AZN) and Bristol Myers Squibb (BMY) is putting oncology stocks back in focus.The SPDR S&P Biotech ETF (XBI) fell 7% in July, marking its worst monthly performance since March 2025.Why Bristol My…
AstraZeneca NYSE:AZN, a global pharmaceutical company focused on oncology and other major therapeutic areas, could gain a potential new cancer treatment with estimated peak sales between $3 billion and $5 billion after a late-stage study produced positive topline results. Sonesitatug vedotin is bei…
AstraZeneca reports positive Phase III overall‑survival results for sonesitatug vedotin in advanced/metastatic gastric cancer; trial met primary and key secondary OS endpoints, no
AstraZeneca NYSE:AZN, a global pharmaceutical company focused on medicines including cancer and rare-disease treatments, maintained its 2026 and 2030 forecasts after second-quarter core earnings exceeded market expectations, helping ease some investor concern following recent clinical-trial setback…
AstraZeneca AZN reported second-quarter 2026 core earnings of $2.63 per share, which beat the Zacks Consensus Estimate of $2.50. Earnings rose 21% year over year on a reported basis and 18% at constant exchange rate (CER).Total revenues of $15.38 billion rose 6% on a reported basis and 5% at CER, b…
Revised summary: Strong H1 2026 with 6% revenue and 11% core EPS growth, driven by innovative medicines and robust pipeline. Oncology and rare disease saw double-digit growth; respiratory and immunology offset generic losses. Confidence in reaching $80B revenue by 2030 remains high, backed by a div…
Positive high-level results from the CLARITY-Gastric01 global Phase III trial showed that sonesitatug vedotin (Sone-Ve) demonstrated a statistically significant and highly clinically meaningful improvement in overall survival (OS) in 2nd and later-line Claudin 18.2-positive advanced gastric cancers…
AstraZeneca (AZN) reported six positive Phase III readouts and gained initial regulatory approvals for multiple new molecular entities, signaling pipeline momentum relevant for tra
Revenue grew 6% at CER in H1 2026, led by 15% oncology growth and strong rare disease performance, while BioPharmaceuticals declined due to LOE impacts. Pipeline momentum continued with six positive Phase III readouts and first approvals for multiple NMEs.Original document: AstraZeneca PLC [AZN] Sl…
RNS Number : 8703N AstraZeneca PLC 27 July 2026 27 July 2026Update on Phase III trial of Ultomiris in adults and adolescents with thrombotic microangiopathy after haematopoietic stem cell transplantHigh-level results from the ALXN1210-TMA-313 Phase III clinical trial showed that Ultomiris (ravu…
AstraZeneca (LSE:AZN) sticks to mid- to high-single-digit 2026 revenue and low-double-digit core EPS guidance while facing FDA review delays for Etcamah and strong DESTINY-Breast09 data for Enhertu, ahead of Q2 results and a royalty deal on cliramitug that could pay up to $425M.Previous Week Recap…
FDA delayed decision on AstraZeneca’s Etcamah, allowing updated pivotal trial data showing reduced risk of progression or death versus standard care; study continues to evaluate su
EU approved AstraZeneca’s Etcamah with CDK4/6 inhibitor as first‑line treatment for advanced ER+ breast cancer — regulatory OK for this indication and combination.AstraZeneca’s cli
AstraZeneca's Zegfrovy approved in US and China for adults with EGFR exon20 insertion NSCLC after platinum chemo; granted Breakthrough Therapy for first-line use and listed in NCCN
Shares of BridgeBio (BBIO) jumped 16% on Thursday after its competitor experienced a major setback in the transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) treatment market.AZN-IONS Trial SetbackAstraZeneca (AZN) and Ionis (IONS) announced on Thursday that their late-stage CARDIO-TTRansform t…
AstraZeneca NYSE:AZN fell 8.71% intraday after the British-Swedish drugmaker disclosed that the Phase III CARDIO-TTRansform trial of Wainua (eplontersen), co-developed with Ionis Pharmaceuticals NASDAQ:IONS, failed to meet its primary efficacy endpoint. The trial evaluated Wainua's ability to reduc…
RNS Number : 6049L AstraZeneca PLC 09 July 2026 [This announcement contains inside information]9 July 2026Update on CARDIO-TTRansform Phase III trial for Wainua (eplontersen) in adults with transthyretin-mediated amyloid cardiomyopathyThe CARDIO-TTRansform Phase III trial1 for AstraZeneca and I…
By Tharuniyaa LakshmiLondon's FTSE 100 ended lower on Monday as losses in precious metal miners and drugmakers including AstraZeneca weighed, while easyJet topped the midcap index after agreeing to a takeover offer.The blue-chip FTSE 100 index CURRENCYCOM:UK100 fell 0.3% to 10,651.8 points at close…
